June 21 2017: In a letter signed by 34 health and consumer groups to the HHS, we asked for stronger action against antibiotic resistance by improving tracking, using fewer antibiotics on farms, and supporting research to keep people safe.
Read More »On Health Policy
NCHR Remarks to the FDA Science Board on Patient Engagement
The National Center for Health Research tells the FDA it’s important to hear from real patients, not just those backed by drug companies, so that decisions about new medicines and treatments are safer and more fair.
Read More »Letter Opposing Amendments to FDA’s User Fee Program that Weaken Patient Safeguards
June 5, 2017. When an unproven assertion of safety and effectiveness is relied on to market a medical product, the resulting harm may be severe—even life-threatening.
Read More »NCHR Testimony to FDA in Preparation for the 2017 International Cooperation on Cosmetics Regulation (ICCR) Meeting
Megan Polanin, May 25 2017: The National Center for Health Research is asking the FDA and international cosmetic regulators to take action on harmful chemicals in beauty products. They point out that substances like phthalates and parabens, found in everyday items like lotions and toothpaste, can affect hormones and may harm children’s development.
Read More »Nonprofit Groups’ Letter to Secretary Price on the Tobacco “Deeming Rule”
May 17, 2017. In light of the overwhelming record evidence compiled by the FDA, there is no public health justification for the FDA to reconsider the deeming rule, or to postpone the implementation of its provisions.
Read More »